申请人:GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
公开号:US10407407B2
公开(公告)日:2019-09-10
Compounds of formula (I): wherein X, Y, R1 and R3-R11 are as herein defined, and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.